

Life expectancy and healthcare costs for patients with rheumatoid arthritis

9 December 2020

A new study published in *Arthritis & Rheumatology* suggests that recent advances in the treatment of rheumatoid arthritis have prolonged patients' lives but also increased healthcare costs.

For the study, <u>investigators</u> examined medical claims data from the National Health Insurance of Taiwan, identifying 29,352 new cases of rheumatoid <u>arthritis</u> from 2003-2016.

The life expectancy after rheumatoid arthritis diagnosis was 26.3 years, and the lifetime cost was estimated to be US \$72,953 after disease-modifying antirheumatic drugs called biologics became available in 2003.

"After the availability of biologics, rheumatoid arthritis patients appeared to live longer with higher lifetime expenditures that should be monitored and evaluated for cost-effectiveness," the authors wrote.

More information: *Arthritis & Rheumatology*, DOI: 10.1002/art.41597

Provided by Wiley

APA citation: Life expectancy and healthcare costs for patients with rheumatoid arthritis (2020, December 9) retrieved 23 August 2022 from https://medicalxpress.com/news/2020-12-life-healthcare-patients-rheumatoid-arthritis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

1/1